Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Teva Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Doug who wrote (153)	2/11/1998 6:55:00 AM
From: LLLefty	Read Replies (1) \| Respond to of 340

I see in an interview with Reuters that CFO Seusskind predicts Copaxone will be profitable "for full-year '98," attributes some of the abnormal marketing costs to earlier than expected approval in Canada and, interestingly, acknowldges that Hoescht Marion was more on target than TEVA in its estimate of the number of Copaxone users (6000) by the end of '97. Having had a profitable run of seven years in trading TEVA, it might be time to let it go. i think it's worth another quarter or so, not because of sentiment but, rather, in view of the fact that it thas taken all its costs in the Biovail buy. Agree that the Health Fund in israel is one big mess but that may be far more than offset by a healthy increaae in its generic revenues abroad.